Cabozantinib Plus Nivolumab Improves Efficacy Over Sunitinib in mRCC
October 31st 2020Ulka Vaishampayan, MD, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib plus nivolumab as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.
Watch
Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?
October 29th 2020Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.
Watch